Compare TransMedics Group Inc (TMDX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs ProShares UltraPro S&P500 — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while ProShares UltraPro S&P500 trades at $141.44. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | UPRO | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $150.42 | $150.93 |
52-Week Low | $61.99 | $89.29 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
UPRO trades at $138.50, down 0.4% on the day, with technical indicators showing a bearish bias as the stock faces resistance near $140-141 levels. The overall technical signal is bearish with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights broader S&P 500 concerns about valuation levels and market concentration in tech stocks, creating headwinds for leveraged ETFs like UPRO.
The outlook for UPRO remains challenged by elevated market valuations and technical resistance. Investment opportunity exists if the S&P 500 breaks through current resistance levels, but risks include continued market volatility and potential mean reversion in tech-heavy indices. The bearish technical setup suggests caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
